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Abstract
Purpose There is no consensus on quality of life (QOL) in patients with acromegaly requiring medical treatment after surgery 
compared with those achieving remission by surgery alone.
Methods QuaLAT is a cross-sectional study comparing QOL in surgery-only treated acromegaly patients versus those requir-
ing medical treatment post-surgery. Patients attending clinics were identified and divided into—Group 1: patients who had 
surgery only and were in biochemical remission, Group 2: all patients on medical treatment post-surgery, Group 3: patients 
from Group 2 with biochemical control. Participants were asked to fill three questionnaires; Acromegaly Quality of Life 
Questionnaire (ACROQOL), 36-Item Short Form Survey (SF36), and Fatigue Severity Scale (FSS).
Results There were 32 patients in Group 1 and 25 in Group 2. There was no difference in QOL scores between groups 1 and 
2, as measured by ACROQOL (mean difference [MD] = − 2.5, 95% CI − 16.6 to 11.6; p = 0.72), SF36v2 [Physical compo-
nent score (PCS) MD = − 4.9, 95% CI − 10.9 to 1.2; p = 0.12; mental component score MD = − 3.0, 95% CI − 10.5 to 4.4; 
p = 0.44], or FSS (MD = − 0.004, 95% CI − 1.14 to 1.33; p = 0.1). Comparison between groups 1 and 3 however showed that 
PCS (and 3 subdomains) was significantly better in group 3 (MD = − 8.3, 95% CI − 14.8 to -1.8; p = 0.01). All three QOL 
scores were lower when compared with healthy controls.
Conclusions Medical treatment not only achieves a QOL comparable to surgery, it may also be associated with better QOL 
in physical subdomains. When compared with healthy controls, QOL remains worse in treated acromegaly patients compared 
to controls.
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Introduction
Acromegaly results from excessive secretion of growth hor-
mone (GH) from tumours usually originating from pitui-
tary somatotroph cells. The excess GH then stimulates the 
liver to produce insulin-like growth factor-1 (IGF-1), which 
causes most of the clinical manifestations of acromegaly [1]. 
Although the incidence of acromegaly has increased, it is a 
rare disease with an estimated prevalence of 8.6 cases per 
100,000 [2]. For any chronic disease, improvement in the 
quality of life (QOL) is an important patient-related health 
outcome goal [3]. Different acromegaly treatment modalities 
have resulted in a clear reduction in mortality and morbid-
ity [4] and it is well established that symptoms and QOL 
improve during acromegaly treatment [5], but in a relatively 
recent systematic review it was concluded that there is no 
overall consensus if any particular treatment is superior to 
the other in improving QOL [6].
The first-line treatment for acromegaly is trans-sphe-
noidal surgery (TSS), to remove or debulk the tumour [7]. 
However, if surgery is unable to achieve disease remis-
sion, medical treatment, such as somatostatin receptor 
ligands (SRL), dopamine agonists (DA), and pegviso-
mant are recommended to achieve biochemical control. 
Conventional radiotherapy or stereotactic radiosurgery 
(STRS) is considered if medical treatment is ineffective 
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or intolerable and to treat residual tumour. While surgery 
can achieve remission in two-thirds of the cases [8], a 
significant proportion of patients will require some form 
of medical treatment afterwards to achieve hormonal con-
trol. Unfortunately irrespective of biochemical control 
health related quality of life remains impaired [6].
QoL reflects the subjective perception of health and 
effects of a disease. QOL in acromegaly has been a sub-
ject of interest in several published studies. Various vali-
dated questionnaires have been used to assess QOL in 
these patients. The most popular of these is Acromegaly 
Quality of Life Questionnaire (ACROQOL) developed by 
Webb et al. in 2002, which is a validated questionnaire for 
acromegaly patients [9]. Several other questionnaires have 
been used in various studies such as Patient-Assessed 
Acromegaly Symptom Questionnaire (PASQ) [10], and 
several other generic questionnaires such as 36-Item 
Short Form Survey (SF36) [11] and EuroQol-5 Dimen-
sions (EQ-5D) [10]. Assessing the effects of symptoms 
and QOL is essential when looking at treatment outcomes 
[5].
When studies have assessed QOL in acromegaly the 
focus seems to be either on the effect of surgery [11, 
12] or medications alone [13–15] or comparison of 
various medication combinations [16, 17]. It is still 
not clear if there is any difference in QOL among those 
who achieve remission by surgery only and those who 
require additional medical treatment post-surgery. Our 
literature review identified only one cross sectional study 
which looked at this question in the Japanese popula-
tion [18]. They found that QOL is worse in medically 
treated patients, but this was a relatively small sized 
study (n = 26). We also found two older studies which 
directly compare QOL between those treated with sur-
gery and those receiving medical treatment longitudi-
nally both as first line treatment [19, 20]. These studies 
showed that the QOL was not different between the two 
groups, despite having improved from baseline. Another 
study from France showed that there was no difference 
in QOL among controlled patients whether treated with 
surgery ± medications or medications alone, however, 
among uncontrolled patients one subscale (psychological 
appearance) was better among surgical patients [21]. A 
significant proportion of patients will require some form 
of medical treatment post-surgery to control their IGF-1 
levels. However, there is no clear consensus in the pub-
lished literature on how the QOL in this group compares 
with those who achieve remission by surgery alone.
We therefore carried out a study to assess whether 
QOL between patients who have achieved remission post-




QuaLAT (Quality of Life after Acromegaly Treatment) is a 
cross-sectional study carried out at the Department of Endo-
crinology, Sheffield Teaching Hospitals NHS Foundation 
Trust, a tertiary referral centre where all patients, aged 18 
or above, with a histological diagnosis of a GH producing 
pituitary adenoma (diagnosed at least 6 months ago) were 
identified via our database. Exclusion criteria included hav-
ing only non-surgical treatment for acromegaly, inability to 
provide informed consent, having a dire prognosis, or severe 
comorbidities unrelated to acromegaly which according to 
investigators may confound results. After exclusions, prelim-
inary data for the remaining patients were collected to iden-
tify those who underwent trans-sphenoidal surgery (TSS) 
and went into disease remission biochemically (Group 1); 
that is achieved IGF1 levels within the age-and sex-specific 
reference range and a growth hormone suppressed level < 0.3 
µg/L post OGTT and/or a growth hormone day curve aver-
age < 1.6 µg/L. Those who did not achieve biochemical 
remission after surgery and therefore required further medi-
cal treatment to control the disease were included in the 
other group (Group 2), irrespective of their biochemical 
status. There were some patients in Group 2 who had their 
last IGF-1 values and growth hormone levels outside the ref-
erence range. To avoid any potential confounding due to this 
factor, another group (Group 3) was crafted for the purpose 
of analysis, including only those patients from Group 2 who 
had controlled biochemistry.
The study was registered with Sheffield Teaching Hos-
pitals research and development department (Reference 
STH20344). The study was approved by the Yorkshire and 
the Humber Research Ethics Committee (REC reference 
19/YH/0373).
Study design and aims
In this study we aimed to compare the quality of life in 
those who were treated with surgery only vs those treated 
with surgery and medications for acromegaly, at a single 
tertiary care centre.
Eligible patients were approached via telephone and 
informed about the study. The willing participants were 
then posted the patient information sheet, a consent form, 
and the QOL questionnaires with two return envelopes to 
post back consent and questionnaires separately to main-
tain confidentiality. Phone numbers to contact the research 
team were provided in the patient information sheet, in 
case they had any additional questions or concerns.
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Those who did not reply back within 28 days were given 
another phone call to check if they are still interested in 
participating in the study. If the interest was expressed 
once again, they were given another 28 days to send the 
documents. If the research team was unable to contact the 
patients, or the documents were not received within 28 
days, it was deemed that the patients were no longer inter-
ested and therefore removed from the study.
Quality of life measurement
All the recruited patients were asked to fill three question-
naires to measure their QoL. One of these was a disease-
specific questionnaire (ACROQOL) and the other two 
were generic questionnaires; SF36 and Fatigue sever-
ity scale (FSS). The permissions to use ACROQOL and 
SF36v2 were obtained prior to the study, while this was 
not required for FSS as it was freely available to use.
(1) ACROQOL
ACROQOL consists of 22 questions, each having five 
options of responses scoring 1–5. The maximum score that 
can be reached is 110 (100%) which reflects the best QoL, 
with 22 (0%) being the lowest possible score. The score is 
calculated by the following equation [22]:
Where L is the lowest score of the subdomain of interest 
and H is the highest score of the same subdomain. There 
are two main categories for these questions: physical and 
psychological function, with the latter further subdivided 
into areas related to appearance and personal relationships.
(2) Short form 36 (SF 36)
The SF36 is a questionnaire widely used for assessing 
health-related QoL. It is not disease-specific but has been 
used in acromegaly patients previously [11]. It consists of 
eight scales: physical functioning (PF), role-physical (RP), 
bodily pain (BP), general health (GH), vitality (VT), social 
functioning (SF), role-emotional (RE), and mental health 
(MH). The first four scales are related to physical health 
with the last four related to mental health. Like ACROQOL, 
final score is a percentage score with higher scores reflecting 
better QOL and vice versa. Calculation of the score is done 
in two steps: first pre-coded numeric values as assigned to 
the scores recorded by the participant according to the scor-
ing key and second, the items in same scale are averaged 




(3) Fatigue severity scale (FSS)
FSS is also a generic questionnaire, which consists of 9 
questions with the patients score from 1 to 7 (1 means strong 
agreement and 7 means strong disagreement) assessing a 
specific acromegaly related symptom and its consequences. 
The questions evaluate the effects of fatigue on subject’s 
motivation, exercise, physical functioning, interference in 
work, family and social life. The total score is calculated by 
either determining the mean of all scores. Unlike the first 
two questionnaires, higher score signifies worse QOL.
The demographic, treatment and biochemical data were 
collected for the successfully recruited patients. This was 
done by reviewing patients’ electronic and paper case notes. 
In addition to age, gender, and ethnicity, the demographic 
data included the presence or absence of various co-mor-
bidities often linked with acromegaly. The treatment data 
included the date of surgery, type of medications used to 
treat acromegaly (if any), use of conventional radiotherapy 
or stereotactic radiosurgery, and current hormone require-
ments. Latest IGF-1 values within the last 12 months of fill-
ing the questionnaires were recorded. All the IGF-1 values 
were measured using validated radioimmunoassay (Mediag-
nost GmBH, Reutlingen, Germany).
Sub analysis
To assess how our final results related to the normal healthy 
population we compared our results from all of the three 
questionnaires to those published in the literature. For this 
comparison, we selected studies which reported QOL in 
a large number of healthy participants and the population 
demographics were largely similar to our study groups and 
that reported the mean and standard deviation.
Our literature search identified only one study that 
reported the ACROQOL scores in a healthy non-diseased 
population as controls to validate their results [24]. The 
study participants in this study were Spanish and obese 
[body mass index (BMI) > 30 kg/m2], however the mean 
BMI was not provided. In case of SF-36, we selected the 
study reported by Jenkinson et al. [25] which reported scores 
from a very large group from the UK population (n = 8889) 
to test its reliability and consistency. Lastly, for FSS, the 
study reported by Ongre et al. [26] was chosen. This study 
reported FSS scores from 170 control participants from Nor-
way and compared with scores from patients with Parkin-
son’s disease.
Statistical analysis
All of the data were analysed using SPSS version 25 and 
GraphPad. Rates and percentages were calculated for cate-
gorical data. Comparison between continuous variables were 
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summarised as mean difference (MD) and 95% confidence 
intervals (CI) of the differences as well as means and stand-
ard deviations (SD). Differences between the groups were 
tested by an independent sample T-test. A p-value of < 0.05 
was considered significant for the study and two-tailed tests 
were used. The differences in quality of life scores between 
three groups were analysed by ANOVA followed by Fisher’s 
least significance difference (LSD) test for post-hoc analysis. 
The differences in QOL scores between study cohort and 
healthy population was performed by independent sample 
T-test using GraphPad online calculator (https:// www. graph 
pad. com/ quick calcs/ ttest1. cfm).
Results
The total number of acromegaly patients who were attending 
Sheffield Teaching Hospital clinics identified via our data-
base was 142. Those who did not meet the inclusion criteria 
were excluded and the remaining (n = 107) were invited for 
the study. Of these, 67 patients were successfully approached 
and showed interest to participate. These patients were then 
posted the study documents including questionnaires. At 
the end of the study we received completed questionnaires 
from 57 participants, who were included in the final analy-
sis. 32 participants had only surgical treatment and were in 
remission post-surgery (Group 1), while the remaining 25 
patients had required some form of medical therapy after 
surgery (Group 2). Since there were some patients in this 
Group 2 who were still biochemically uncontrolled based 
on IGF1 levels above the normal range despite treatment, 
a third medically controlled only group was created for the 
purpose of analysis (Group 3) (Fig. 1).
Table 1 summarises the comparison of baseline demo-
graphic, treatment and biochemical data between the three 
groups. All of the patients in this study were Caucasians. 
There were no significant differences between Group 1 
and 2 in age, duration of disease, gender distribution, use 
of conventional radiotherapy, or current requirement of 
hormonal treatments. Most of the patients in both groups 
were on single hormone replacement (12/14 in group 1 and 
10/12 in group 2). The hormonal treatments were adequately 
replaced as patients are under regular endocrine follow up. 
More patients in the medical group underwent STRS, as one 
might expect. Also, there were a few uncontrolled patients 
in group 2 (n = 7), as mentioned earlier.
Groups 1 and 3 were similar with the exception of STRS. 
There were more males in the Group 3 (n = 12/18; p = 0.07). 
There was no significant difference in the incidence of 
other acromegaly related conditions [hypertension, T2DM, 
ischaemic heart disease, cardiomyopathy, heart failure, car-
diac arrhythmias, obstructive sleep apnoea, mental health 
disorders such as anxiety or depression, dyslipidaemia (or 
current use of statins or fibrates), valvular heart disease (at 
least moderate aortic or mitral regurgitation), and bowel 
cancer] across all of the groups. The majority of patients in 
the medical group were on SRLs either alone (n = 16) or in 
combination with cabergoline (n = 1). Five patients were on 
cabergoline alone, and three patients were on pegvisomant 
treatment.
There was no difference in QOL scores between our 
main groups 1 and 2, as measured by all of three question-
naires (Table 2). Further comparison between subdomains 
Fig. 1  Schematic representation 
of study illustrating how the 
final number of patients were 
reached in groups 1 (surgery 
only), 2 (surgery followed by 
medications), and 3 (surgery 




and individual questions for all questionnaires (data not 
shown here) was also non-significant. However interest-
ingly, when only medically controlled patients (Group 3) 
were compared with those in the surgical group, physi-
cal component score (PCS) of the SF36 questionnaire 
(and three of its subdomains: PF [MD = − 19.2, 95% 
CI − 37.2 to − 1.2; p = 0.04], RP [MD = − 22.8, 95% 
CI − 42.1 to − 3.5; p = 0.02], BP [MD = − 20.5, 95% 
CI − 36.3 to − 4.7; p = 0.01]) was significantly better in 
the medically controlled only patients (PCS MD = − 8.3, 
95% CI − 14.8 to − 1.8; p = 0.014). This trend was also 
noted in the ACROQOL physical domain however the p 
value fell just short of significance (MD = − 15.4, 95% 
CI − 33.1 to 2.2; p = 0.09). A multivariate model includ-
ing various variables (age, gender, duration of disease, 
hormone replacement, radiotherapy) also confirmed that 
while there was no difference between groups 1 and 2, the 
PCS of group 3 (and two of its subdomain [RP and BP] 
remained significantly better than group 1 [p = 0.04]).
QOL in acromegaly patients’ vs healthy population
Figure 2 below shows the comparison of our ACROQOL 
scores with 157 healthy but obese controls from a Spanish 
population as reported by Webb et al. [24]. It can be seen 
that the difference in QOL is mainly in the psychological 
dimensions. Analogous comparisons of SF36 subdomains 
[25] and FSS scores [26] also mirrors the inferior QOL in 
all treated groups in our study (Figs. 3 and 4).
Discussion
Our study shows that patients who had medical treatment 
after surgery have a similar QOL when compared to patients 
with acromegaly who are in remission after surgery alone. 
Nonetheless, while treatment improves the QOL, it remains 
worse in acromegaly treated patients compared to the healthy 
population. Our findings highlight the important role medi-
cal treatment has in patients with uncontrolled acromegaly 
but also demonstrates the unmet need to develop more effec-
tive therapeutic strategies that, not only control the disease 
biochemically, but also improve patient well-being. In addi-
tion to ACROQOL, the only validated acromegaly question-
naire, we specifically assessed fatigue, an acromegaly related 
typical symptom, using FSS, a questionnaire that had never 
been studied previously in this patient group. The survey 
gives us insight on how a symptom could impact QOL, 
which was worse than in normal controls, and highlights 
the importance of assessing symptoms when studying treat-
ment interventions in acromegaly. The third questionnaire 
we used was SF36, which is the most widely used QOL 
assessment tool globally and has been used frequently in 
acromegaly [11, 12].
Table 1  Table showing baseline demographic, treatment and biochemical data comparison between the three groups














Mean age (years) ± SD 61.0  ±  11.3 56.7  ±  13.4 56.3  ±  12.4 0.20 0.19
Mean duration of disease (years) ± SD 9.9  ±  7.1 11.1  ±  8.5 11.9  ±  9.3 0.58 0.43
Radiotherapy (%) 3/32 (9%) 6/25 (24%) 5/18 (28%) 0.13 0.09
Stereotactic radiosurgery (STRS) (%) 3/32 (9%) 8/25 (32%) 6/18 (33%) 0.03* 0.03*
Hormone requirement (%) 14/32 (44%) 12/25 (48%) 10/18 (56%) 0.75 0.42
Gender (F/M) 19/13 10/15 6/12 0.15 0.07




Controlled = 18 0.001* -
Hypertension (%) 20/32 (63%) 16/25 (64%) 12/18 (67%) 0.91 0.77
Type 2 diabetes mellitus (%) 7/32 (22%) 7/25 (28%) 6/18 (33%) 0.59 0.38
Mental health disorder (%) 11/32 (34%) 11/25 (34%) 7/18 (39%) 0.46 0.75
Obstructive sleep apnea (%) 4/32 (13%) 3/25 (12%) 2/18 (11%) 0.95 0.89
Dyslipidaemia (%) 14/32 (44%) 10/25 (40%) 8/18 (44%) 0.78 0.96
Osteoarthritis (%) 6/32 19%) 6/25 (24%) 5/18 (28%) 0.63 0.46
Arrhythmias (%) 2/32 (6%) 2/25 (8%) 1/18 (6%) 0.80 0.92
Valvular heart problems (%) 1/32 (6%) 1/25 (4%) 0/18 (0%) 0.86 0.45
IHD/Heart Failure/Cardiomyopathy (%) 1/32 3%) 2/25 (4%) 1/18 (6%) 0.41 0.67
Bowel cancer (%) 1/32 (3%) 0/25 (0%) 0/18 (0%) 0.37 0.45
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QOL in patients with acromegaly is a concern. As first-
line treatment to achieve remission in acromegaly, surgery 
is recommended as it can achieve higher remission rates 
compared with first line medical treatment (66% vs 45%) 
[10]. For those unable to achieve remission by surgery, long 
term medical treatment is the mainstay therapeutic strategy 
besides radiotherapy and a significant number of patients 
do achieve biochemical remission on maximal treatment, 
sometimes needing combination regimes [9]. Conversely 
long-term biochemical cure is not usually associated with 
normal life quality as highlighted by our findings. This has 
been shown by a number of studies but in view of the rarity 
of the disease most have used heterogenous groups and been 
cross-sectional as opposed to prospective [6]. Study popula-
tions vary within studies differing in treatment stage, disease 
control, length of remission and treatment received. This 
makes data less accurate and at times difficult to interpret. 
Unlike these studies we tried to create study groups which, 
apart from treatments received, were less heterogenous and 
studied sometime after surgery. Our groups did not differ in 
age, duration of disease from diagnosis, presence of hypopi-
tuitarism, presence of metabolic complications and mental 
health issues. Irrespective of this all our groups still achieved 
a QOL which is lower than the normal population.
Data from older longitudinal studies comparing QOL 
in surgical and medical treatment only (i.e., no surgery) 
Table 2  Comparison of QOL scores between surgical and medical group, calculated using ANOVA and Fisher’s least significance difference 

























51.3  ±  27.1 53.8  ±  25.5 57.1  ±  27.3 − 2.5 (− 16.7 to 
11.7)





46.4  ±  28.3 54.8  ±  30.8 61.8  ±  31.2 − 8.4 (− 24.4 to 
7.6)












63.5  ±  28.0 62.4  ±  27.4 63.1  ±  28.0 1.1 (− 13.7 to 15.9) 0.89 0.4 (− 15.9 to 16.7) 0.96
FSS mean 
score ± SD




40.6  ±  10.3 45.4  ±  12.3 48.8  ±  11.8 − 4.9 (− 11.0 to 
1.2)





56.9  ±  29.6 69.0  ±  31.2 76.1  ±  31.5 − 12.1 (− 28.4 to 
4.2)





48.0  ±  29.5 62.5  ±  34.9 70.8  ±  34.8 − 14.5 (− 32.0 to 
3.0)
0.10 − 22.8 (− 42.1 to 
− 3.5)
0.02*
Bodily pain (BP) 49.0  ±  22.6 60.9  ±  31.4 69.5  ±  27.2 − 11.9 (− 26.2 to 
2.4)





41.2  ±  25.7 48.7  ±  32.8 55.6  ±  35.1 − 7.5 (− 23.7 to 
8.8)






39.3  ±  12.0 42.3  ±  15.8 43.7  ±  15.7 − 3.0 (− 10.7 to 
4.6)





57.3  ±  31.2 65.0  ±  34.9 71.3  ±  31.9 − 7.7 (− 25.1 to 
9.7)
0.38 − 14.0 (− 33.2 to 
5.2)
0.15
Vitality (VT) 34.3  ±  23.3 39.8  ±  31.0 44.4  ±  32.9 − 5.5 (− 20.8 to 
9.8)





52.6  ±  24.8 62.6  ±  29.3 65.0  ±  30.5 − 10.0 (− 24.9 to 
4.9)





58.2  ±  30.7 67.0  ±  32.9 71.5  ±  32.9 − 8.8 (− 25.8 to 
8.2)





have shown that QOL in both groups improves from base-
lines but is not different between the groups at 12 and 48 
weeks [19, 20]. In our study, however, we excluded the few 
patients who required only medical treatment for acromeg-
aly. Most of these patients had either inoperable tumours 
or were not medically fit enough to undergo surgery. These 
Fig. 2  Comparison of mean ACROQL total and domain scores (with standard deviation) of acromegaly groups with healthy and obese Spanish 
population (asterisk symbol representing significant differences between groups; ***p < 0.001, **p < 0.01, *p < 0.05)
Fig. 3  Comparison of mean SF36 subdomain scores (with standard deviation) of acromegaly groups with healthy controls (asterisk symbol rep-
resenting significant differences between groups; ***p < 0.001, **p < 0.01, *p < 0.05)
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factors, therefore, would have confounded the QOL scores 
and besides in clinical practice, the vast majority of patients 
would first undergo surgery in line with the guidelines.
A Japanese study from 2014 also compared the QOL 
between surgical and medical patients [18]. This study was 
a cross-sectional study and showed that the QOL in surgical 
patients (n = 12) was better than those who were medically 
treated (n = 14). The authors also postulated that radiother-
apy played an important role in lowering QOL scores in 
medical patients, as the difference between QOL scores was 
less significant once those with radiotherapy were excluded 
(n = 4) from the medical group. The results from our study 
are dissimilar to these findings however our study had more 
than twice the number of subjects. Besides, it is not clear 
from their published results, how many of the patients in the 
medical group also had surgery. This along with the differ-
ences in ethnicity between these two studies could possibly 
explain the dissimilarity in the results. In addition, we were 
also unable to confirm their finding with regards to radio-
therapy, as removing radiotherapy patients from both groups 
in our study didn’t alter the results, and the QOL scores 
remained comparable (supplementary table 1).
We have also found that medically controlled patients 
have better physical scores: SF36 PCS and possibly, 
ACROQOL physical subdomain. This could be related to 
the improvement in external features of the disease, better 
control of physical symptoms, or perhaps due to a sense of 
physical well-being from frequent monitoring and reassur-
ance. Higher proportion of men in the medically controlled 
group, could have been a contributing factor since QOL 
scores in the general population tend to be worse in females 
[27] and in acromegaly QOL is affected more in females due 
to delay in diagnosis and added comorbidities [28] and more 
socioeconomic burden of the disease [29]. However, since 
the difference was still significant adjusting for gender, it 
was not a confounding factor in our study.
The reason for a low QOL in acromegaly patients despite 
treatment is debatable, but there are several contributing 
factors. Despite substantial improvements in healthcare in 
the recent past, there is still considerable delay in diagno-
sis of acromegaly, with some studies estimating the delay 
to be around 8–10 years from the onset of symptoms [30]. 
Owing to this delay severe irreversible damage such as 
changes in joint, soft tissues, voice, and physical appear-
ance have already occurred by the time of diagnosis. Hence 
treatment, at best, can only slow down the progression of 
these changes, as the damage has already taken place [31]. 
There is an increased incidence of other chronic conditions 
in acromegaly which impair QOL such as depression [32], 
high BMI [33], type 2 diabetes [34]. Despite treatment, 
these conditions continue to progress in most cases, fur-
ther deteriorating QOL. Some treatment options or resulting 
consequences could also be a contributing factor such as 
radiotherapy [35, 36] or hypopituitarism [36] both of which 
have been noted to reduce QOL in some studies. However, 
the systematic review by Geraedts et al. [6] didn’t confirm 
the link between hypopituitarism and QOL. An interesting 
but unproven hypothesis is that current criteria for disease 
remission rely heavily on post treatment IGF-1 or GH lev-
els. This may not reflect the true tissue exposure of GH and 
Fig. 4  Comparison of mean 
FSS scores (with standard 
deviation) of acromegaly groups 
with healthy controls (asterisk 
symbol representing significant 
differences between groups; 




therefore may have a role to play in persistent low QOL in 
acromegaly despite treatment.
One of the main limitations of our study is the cross-sec-
tional design and therefore absence of longitudinal data and 
control group. However, the latter was countered by includ-
ing QOL data from large population cohorts. Secondly, our 
sample size was relatively small which may have decreased 
the statistical power. Also, the BMI data for the patients in 
this study was not available to us, which could be a poten-
tial confounding factor. Long-term, large prospective inter-
ventional studies looking at effects of different therapeutic 
strategies on symptoms and QOL are necessary to confirm 
our findings.
In conclusion, while surgery is superior in achieving 
biochemical remission in acromegaly, we have shown that 
medical treatment achieves similar QOL. In patients who 
do not achieve biochemical remission after surgery, medical 
treatment not only maintains QOL comparable to surgical 
patients in remission, but may also be associated with better 
QOL in physical subdomain. Secondly, compared to healthy 
controls, the QOL remains worse in acromegaly irrespec-
tive of the type of treatment. Strategies to diagnose acro-
megaly earlier and novel treatment modalities are required 
to improve this important patient-related health outcome.
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